Back
Blueprint Medicines Stock Price Chart
Free Stock Analysis Report: See The True Value of Any Stock
Analyze Any Stock Free
Sell
43
BPMC
Blueprint Medicines
Last Price:
$102.47
Seasonality Move:
5.27%
7 Day Trial
ALL ACCESS PASS
$
7
Try a Free Stock Analysis With Definitive Buy Sell Hold Ratings
Analyze Any Stock Free-
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and BPMC is experiencing buying pressure, which is a positive indicator for future bullish movement.
Blueprint Medicines Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 91.01 | Buy |
| 20-day SMA: | 91.26 | Buy |
| 50-day SMA: | 93.56 | Buy |
| 200-day SMA: | 96.81 | Buy |
| 8-day EMA: | 92.7 | Buy |
| 20-day EMA: | 91.91 | Buy |
| 50-day EMA: | 92.32 | Buy |
| 200-day EMA: | 91.6 | Buy |
Blueprint Medicines Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.02 | Buy |
| Relative Strength Index (14 RSI): | 65.19 | Buy |
| Chaikin Money Flow: | 1951173 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (88.25 - 95.81) | Buy |
| Bollinger Bands (100): | (87.04 - 95.76) | Buy |
Blueprint Medicines Technical Analysis
| Dec 27 | Dec 30 | Dec 31 | Jan 2 | Jan 3 | Jan 6 | Jan 7 | Jan 8 | Jan 10 | Jan 13 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec | Jan | |||||||||
| 27 | 30 | 31 | 02 | 03 | 06 | 07 | 08 | 10 | 13 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Blueprint Medicines Stock
Is Blueprint Medicines Stock a Buy?
-
Blueprint Medicines share price is 103.36 while BPMC 8-day simple moving average is 91.01, which is a Buy signal.
-
The stock price of BPMC is 103.36 while Blueprint Medicines 20-day SMA is 91.26, which makes it a Buy.
-
Blueprint Medicines 50-day simple moving average is 93.56 while BPMC share price is 103.36, making it a Buy technically.
-
BPMC stock price is 103.36 and Blueprint Medicines 200-day simple moving average is 96.81, creating a Buy signal.
BPMC Technical Analysis vs Fundamental Analysis
Sell
43
Blueprint Medicines (BPMC)
is a Sell
Is Blueprint Medicines a Buy or a Sell?
-
Blueprint Medicines stock is rated a SellThe current Blueprint Medicines [BPMC] share price is $103.36. The Score for BPMC is 43, which is 14% below its historic median score of 50, and infers higher risk than normal.
Blueprint Medicines Stock Info
Market Cap:
6.6B
Price in USD:
103.36
Share Volume:
2.1M
Blueprint Medicines 52-Week Range
52-Week High:
121.90
52-Week Low:
72.24
Sell
43
Blueprint Medicines (BPMC)
is a Sell
Blueprint Medicines Share Price Forecast
-
What is the Blueprint Medicines stock price today?The Blueprint Medicines stock price is 103.36 USD today.
-
Will BPMC stock go up or go down?Blueprint Medicines> share price is forecast to RISE/FALL based on technical indicators
-
Is Blueprint Medicines overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Blueprint Medicines is overvalued.
Is Blueprint Medicines Stock a Buy?
-
Blueprint Medicines share price is 103.36 while BPMC 8-day exponential moving average is 92.70, which is a Buy signal.
-
The stock price of BPMC is 103.36 while Blueprint Medicines 20-day EMA is 91.91, which makes it a Buy.
-
Blueprint Medicines 50-day exponential moving average is 92.32 while BPMC share price is 103.36, making it a Buy technically.
-
BPMC stock price is 103.36 and Blueprint Medicines 200-day simple moving average is 91.60, creating a Buy signal.
Fundamental Analysis of Blueprint Medicines
Is Blueprint Medicines a good investment?
-
Analysts estimate an earnings increase this quarter of $0.71 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.41 per share, and an increase next year of $2.89 per share.
Technical Analysis of Blueprint Medicines
Should I short Blueprint Medicines stock?
-
BPMC Moving Average Covergence Divergence (MACD) indicator is 0.02, suggesting Blueprint Medicines is a Buy
-
Blueprint Medicines Relative Strength Index (RSI) is 65.19, which suggest Blueprint Medicines is overbought
-
The Bollinger Bands (25) for Blueprint Medicines is (88.25 - 95.81), which suggest Blueprint Medicines is a Buy
-
The Bollinger Bands (100) for Blueprint Medicines is (87.04 - 95.76), which suggest Blueprint Medicines is a Buy
* Blueprint Medicines stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.